Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Metastatic colorectal cancer |
Dose: Intravenous – 5 mg/kg Frequency: every 2 weeks Note: with bolus-IFL |
|
Indication: Metastatic colorectal cancer |
Dose: Intravenous – 10 mg/kg Frequency: every 2 weeks Note: with Oxaliplatin plus leucovorin and 5-fluorouracil |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Administration
- For IV use only
- First infusion over 90 minutes
Side Effect
- Weakness (73-74%)
- Hypertension (23-67%, grades 3/4 8-18%)
- Pain (61-62%)
- Abdominal pain (50-61%, grades 3/4 8%)
- Vomiting (47-52%, grades 3/46-11%)
- URI (40-47%)
- Constipation (29-40%)
- Leukopenia (grades 3/4 37%)
- Proteinuria (36%, grades 3/4 3%)
- Epistaxis (32-35%)
- Ovarian failure (with mFolfox) (34%)
- Diarrhea (grades 3/4 2-34%)
- Stomatitis (30-32%)
- Alopecia (6-32%)
- Neutropenia (grades 3/4 6-27%)
- Headache (26%, grades 3/4 2-4%)
- Dyspnea (25-26%)
- Dizziness (19-26%)
- GI hemorrhage (19-24%)
- Dyspepsia (17-24%)
- Taste alteration (14-21%)
- Dry skin (7-20%)
- Exfoliative dermatitis (3-19%)
- Fatigue (grades 3/4 5-19%)
- Flatulence (11-19%)
- Lacrimation disorder (6-18%)
- Neuropathy (grades 3/4 1-17%)
- Weight loss (15-16%)
- Hypokalemia (12-16%)
- Skin discoloration (2-16%)
- Thromboembolic events (grades 3/4 15%)
- Myalgia (8-15%)
- Hypotension (7-15%)
- Nausea (grades 3/4 4-12%)
- Back pain (undefined)
- Dehydration (grades 3/4 3-10%)
- DVT (6-9%, grades 3/4 9%)
- Polyuria (3-6%)
- Bilirubinemia (1-6%)
- Colitis (1-6%)
- Confusion (1-6%)
- Neutropenia (5%)
- Thrombocytopenia (5%)
- Xerostomia (4-7%)
- Ileus (grades 3/4 4-5%)
- Abnormal gait (1-5%)
- Bone pain (grade 3/4 4%)
- Hyponatremia (grades 3/4 4%)
- GI perforations (Less than 4%)
- Arterial thrombosis (3-4%)
- Intra-abdominal venous thrombosis (grades 3/4 3%)
- Rash desquamation (grades 3/4 3%)
- Syncope (grades 3/4 3%)
- Infusion reaction (Less than 3%)
- Cardio-cerebrovascular arterial thrombotic event (2-4%)
- CHF (2%)
- Wound dehiscence (1%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Irinotecan/5–fluorouracil/leucovorin
|
Increased incidence of epistaxis and grade 1 or 2 hemorrhage
|
|
Live vaccines
|
May result in a reduced immune response
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Recent Hemoptysis
|
Risk of severe bleeding
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Bevacizumab vials are stable at 2 to 8° C. Bevacizumab vials should be protected from light. Do not freeze or shake. Diluted Bevacizumab solutions may be stored at 2 to 8° C for up to 8 hours. Store in the original carton until time of use. No incompatibilities between Bevacizumab and polyvinylchloride or polyolefin bags have been observed.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.